Certain Balance Sheet Components

6 Months Ended

Sep. 30, 2022

Other Liabilities Disclosure [Abstract]

Cash, Cash Equivalents and Restricted Cash

The following represents a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows (in thousands):


	September 30,
	2022		2021
Cash and cash equivalents	$	341,960	$	518,163
Restricted cash (included in other assets)	10,868		10,100
Total cash, cash equivalents and restricted cash	$	352,828	$	528,263

Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash (maturity of three months or less at the time of purchase). Restricted cash consists of funds held or designated to satisfy the requirements of certain agreements that are restricted in their use. As of September 30, 2022 and 2021, restricted cash includes approximately $7.1 million, that is held in an escrow fund for use by Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Pharma, to manage payments for rebates, chargebacks, and similar fees pursuant to the Market Access Services Agreement (see Note 5(F)).

Inventories

Inventories consisted of the following (in thousands):


	September 30, 2022		March 31, 2022
Raw materials	$	9,999	$	663
Work in process	10,829		3,737
Finished goods	2,219		3,184

Total inventories	$	23,047	$	7,584

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):



	September 30, 2022		March 31, 2022
Accrued sales discounts, rebates, and allowances	$	38,620	$	19,390
Accrued compensation-related expenses	18,171		26,389
Accrued R&D expenses	7,081		6,955
Accrued commercial expenses	6,387		7,196
Accrued royalties payable to Takeda	3,769		2,470
Accrued professional fees	3,595		1,340
Accrued income tax payable	2,977		720
Accrued other expenses	2,864		3,309
Deferred product revenue	617		825
Total accrued expenses and other current liabilities	$	84,081	$	68,594